PL4164595T3 - Kompozycje proszku anatabiny - Google Patents
Kompozycje proszku anatabinyInfo
- Publication number
- PL4164595T3 PL4164595T3 PL21730990.5T PL21730990T PL4164595T3 PL 4164595 T3 PL4164595 T3 PL 4164595T3 PL 21730990 T PL21730990 T PL 21730990T PL 4164595 T3 PL4164595 T3 PL 4164595T3
- Authority
- PL
- Poland
- Prior art keywords
- anatabine
- powder compositions
- compositions
- powder
- anatabine powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20180100 | 2020-06-15 | ||
| PCT/IB2021/054692 WO2021255560A1 (en) | 2020-06-15 | 2021-05-28 | Anatabine powder compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4164595T3 true PL4164595T3 (pl) | 2025-11-24 |
Family
ID=71096637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21730990.5T PL4164595T3 (pl) | 2020-06-15 | 2021-05-28 | Kompozycje proszku anatabiny |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230233459A1 (pl) |
| EP (1) | EP4164595B1 (pl) |
| JP (1) | JP2023529411A (pl) |
| KR (1) | KR20230024889A (pl) |
| CN (1) | CN115697299A (pl) |
| BR (1) | BR112022022858A2 (pl) |
| CA (1) | CA3170742A1 (pl) |
| ES (1) | ES3040112T3 (pl) |
| MX (1) | MX2022015578A (pl) |
| PL (1) | PL4164595T3 (pl) |
| WO (1) | WO2021255560A1 (pl) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6595210B2 (en) * | 2000-11-27 | 2003-07-22 | Unisia Jecs Corporation | Inhalator for administering powder composition |
| GB2381750A (en) * | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| CA2963423C (en) * | 2007-03-30 | 2020-07-28 | Philip Morris Products S.A. | Device and method for delivery of a medicament |
| US8207346B2 (en) | 2010-03-23 | 2012-06-26 | Rock Creek Pharmaceuticals, Inc. | Methods of synthesizing anatabine |
| EP3871674B1 (en) | 2010-03-23 | 2024-12-25 | Philip Morris Products S.A. | Use of anatabine for reducing blood serum levels of c-reactive protein in an individual |
| US20130298921A1 (en) * | 2011-06-23 | 2013-11-14 | Rock Creek Pharmaceuticals, Inc. | Inhaler for smoking cessation |
| CN108578405A (zh) | 2011-08-29 | 2018-09-28 | 菲利普莫里斯产品有限公司 | 用于抗炎支持的产品 |
| WO2015009500A1 (en) * | 2013-07-19 | 2015-01-22 | Williams Jonnie R | Volatilized delivery of anatabine for treatment of substance addiction |
| US9585835B1 (en) * | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
| CN109310623B (zh) * | 2016-06-30 | 2022-10-21 | 菲利普莫里斯生产公司 | 尼古丁颗粒 |
| EP3478264B1 (en) * | 2016-06-30 | 2025-11-19 | Philip Morris Products S.A. | Nicotine particles and compositions |
| US11744962B2 (en) * | 2018-03-26 | 2023-09-05 | Philip Morris Products S.A. | Inhaler with composite porous support element |
-
2021
- 2021-05-28 JP JP2022575346A patent/JP2023529411A/ja active Pending
- 2021-05-28 WO PCT/IB2021/054692 patent/WO2021255560A1/en not_active Ceased
- 2021-05-28 US US18/008,793 patent/US20230233459A1/en active Pending
- 2021-05-28 MX MX2022015578A patent/MX2022015578A/es unknown
- 2021-05-28 PL PL21730990.5T patent/PL4164595T3/pl unknown
- 2021-05-28 CN CN202180037424.3A patent/CN115697299A/zh active Pending
- 2021-05-28 CA CA3170742A patent/CA3170742A1/en active Pending
- 2021-05-28 BR BR112022022858A patent/BR112022022858A2/pt unknown
- 2021-05-28 ES ES21730990T patent/ES3040112T3/es active Active
- 2021-05-28 KR KR1020227040215A patent/KR20230024889A/ko active Pending
- 2021-05-28 EP EP21730990.5A patent/EP4164595B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4164595A1 (en) | 2023-04-19 |
| EP4164595B1 (en) | 2025-08-20 |
| MX2022015578A (es) | 2023-01-24 |
| WO2021255560A1 (en) | 2021-12-23 |
| JP2023529411A (ja) | 2023-07-10 |
| CA3170742A1 (en) | 2021-12-23 |
| EP4164595C0 (en) | 2025-08-20 |
| US20230233459A1 (en) | 2023-07-27 |
| BR112022022858A2 (pt) | 2022-12-20 |
| KR20230024889A (ko) | 2023-02-21 |
| ES3040112T3 (en) | 2025-10-28 |
| CN115697299A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201917917D0 (en) | Tobacco composition | |
| GB202013432D0 (en) | Compositions | |
| ZA202403158B (en) | Compositions | |
| PL4065661T3 (pl) | Kompozycje | |
| GB202015836D0 (en) | Compositions | |
| GB202105461D0 (en) | Compositions | |
| GB202102704D0 (en) | Compositions | |
| EP3959988A4 (en) | POWDER COMPOSITION | |
| GB2610026B (en) | Compositions | |
| GB202117953D0 (en) | Aerosol-generating compositions | |
| EP4282826A4 (en) | POWDER COMPOSITION | |
| IL315870A (en) | The compounds containing cannabinoids | |
| GB202014921D0 (en) | Tobacco compositions and preparation thereof | |
| GB202002048D0 (en) | Compositions | |
| EP4164595C0 (en) | ANATABINE POWDER COMPOSITIONS | |
| GB202307490D0 (en) | Powder composition | |
| GB202215776D0 (en) | Powder composition | |
| ZA202210764B (en) | Compositions | |
| GB202118081D0 (en) | Compositions | |
| GB202117074D0 (en) | Compositions | |
| GB202116861D0 (en) | Compositions | |
| GB202116387D0 (en) | Compositions | |
| GB202116388D0 (en) | Compositions | |
| GB202116386D0 (en) | Compositions | |
| GB202115617D0 (en) | Compositions |